Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI

使用超极化氙 MRI 进行肺功能性回避放射治疗

基本信息

  • 批准号:
    10490280
  • 负责人:
  • 金额:
    $ 69.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-17 至 2027-02-28
  • 项目状态:
    未结题

项目摘要

SUMMARY Customized 3D planning of radiation therapy for lung cancer delivers a lethal dose to the tumor region while avoiding important structures (spine) and organs (esophagus, heart, lungs) Since radiation dose to functioning lung is associated with acute radiation pneumonitis and chronic radiation fibrosis, researchers seek to shift dosage preferentially away from lung regions with highest function. Several lung functional imaging modalities have been investigated (ventilation- perfusion SPECT and PET, 4DCT, hyperpolarized 3He). These studies indicate that regional ventilation is not the optimal biomarker. What is needed is a high-resolution imaging modality, tolerable to patients who have difficulty holding their breath, that delineates regions of full lung function warranting preservation, and also identifies regions whose function is irrevocably gone. Hyperpolarized xenon-129 (HXe) MRI provides highly detailed maps of several lung functional characteristics. Its solubility in tissues and affinity for hemoglobin allow it to be used as a tracer for gas exchange kinetics, a so-called “regional DLCO”. Up until now, HXe imaging modalities required long breath holds, which are not well tolerated by lung-compromised patients. We developed an HXe assessment technique that probes several lung function characteristics, including gas exchange to/from red blood cells, with a natural tidal-breathing protocol. Our industrial team developed an automated xenon hyperpolarizer that delivers the required multi-liter volumes at polarizations that approach 50%, enabling this protocol to become routine. We propose a translational study applying HXe MRI to functional avoidance plan optimization to minimize fibrosis in lung cancer patients. To maximize statistical significance, we stratify the patient cohort selecting patients with significant heterogeneity: half with de novo lung cancer with GOLD stage 3+ emphysema comorbidity and half receiving RT for their second (primary) lung cancer. Maps will delineate three functional regions: full function with both ventilation and gas exchange to RBCs (extra importance for avoidance), regions where function is irrevocably absent (reduced avoidance), and other regions where function may be present or recoverable (normal avoidance). In year 1 we conduct an open-label trial to optimize the functional imaging protocols with upgraded hardware. With IRB and DSMB approval, our Phase 2 clinical trial will enroll 70 patients: half receiving standard-of-care treatment and half undergoing RT guided by HXe MRI. Six-month post-treatment assessments include changes in HXe MRI, for regional correlation with local dose. Primary endpoint will be change in DLCO, with secondary endpoints of breathing- related quality of life change from baseline, spirometry/DLCO relative to predicted, incidence/severity of pneumonitis, and change in HXe-MRI.
SUMMARY Customized 3D planning of radiation therapy for lung cancer delivers a lethal dose to the tumor region while avoiding important structures (spine) and organs (esophagus, heart, lungs) Since radiation dose to functioning lung is associated with acute radiation pneumonitis and chronic radiation fibrosis, researchers seek to shift dosage preferentially away from lung regions with highest function. Several lung functional imaging modalities have been investigated (ventilation- perfusion SPECT and PET, 4DCT, hyperpolarized 3He). These studies indicate that regional ventilation is not the optimal biomarker. What is needed is a high-resolution imaging modality, tolerable to patients who have difficulty holding their breath, that delineates regions of full lung function warranting preservation, and also identifies regions whose function is irrevocably gone. Hyperpolarized xenon-129 (HXe) MRI provides highly detailed maps of several lung functional characteristics. Its solubility in tissues and affinity for hemoglobin allow it to be used as a tracer for gas exchange kinetics, a so-called “regional DLCO”. Up until now, HXe imaging modalities required long breath holds, which are not well tolerated by lung-compromised patients. We developed an HXe assessment technique that probes several lung function characteristics, including gas exchange to/from red blood cells, with a natural tidal-breathing protocol. Our industrial team developed an automated xenon hyperpolarizer that delivers the required multi-liter volumes at polarizations that approach 50%, enabling this protocol to become routine. We propose a translational study applying HXe MRI to functional avoidance plan optimization to minimize fibrosis in lung cancer patients. To maximize statistical significance, we stratify the patient cohort selecting patients with significant heterogeneity: half with de novo lung cancer with GOLD stage 3+ emphysema comorbidity and half receiving RT for their second (primary) lung cancer. Maps will delineate three functional regions: full function with both ventilation and gas exchange to RBCs (extra importance for avoidance), regions where function is irrevocably absent (reduced avoidance), and other regions where function may be present or recoverable (normal avoidance). In year 1 we conduct an open-label trial to optimize the functional imaging protocols with upgraded hardware. With IRB and DSMB approval, our Phase 2 clinical trial will enroll 70 patients: half receiving standard-of-care treatment and half undergoing RT guided by HXe MRI. Six-month post-treatment assessments include changes in HXe MRI, for regional correlation with local dose. Primary endpoint will be change in DLCO, with secondary endpoints of breathing- related quality of life change from baseline, spirometry/DLCO relative to predicted, incidence/severity of pneumonitis, and change in HXe-MRI.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEPHEN J KADLECEK其他文献

STEPHEN J KADLECEK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEPHEN J KADLECEK', 18)}}的其他基金

Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI
使用超极化氙 MRI 进行肺功能性回避放射治疗
  • 批准号:
    10299299
  • 财政年份:
    2021
  • 资助金额:
    $ 69.65万
  • 项目类别:
Molecular imaging using hyperpolarized carbon-13
使用超极化碳 13 进行分子成像
  • 批准号:
    7079132
  • 财政年份:
    2006
  • 资助金额:
    $ 69.65万
  • 项目类别:
Molecular imaging using hyperpolarized carbon-13
使用超极化碳 13 进行分子成像
  • 批准号:
    7230103
  • 财政年份:
    2006
  • 资助金额:
    $ 69.65万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 69.65万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 69.65万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 69.65万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 69.65万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 69.65万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 69.65万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 69.65万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 69.65万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 69.65万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 69.65万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了